Skip to content

Study · Not a test of the peptide alone · 2018

2 results

Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.

Wittbrodt ET, Eudicone JM, Farahbakhshian S, McAdam-Marx C

The American journal of managed care1 Apr 2018

PMID29693362 (opens in a new tab)PepBankPUB-29693362
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyOther

    In a US database, patients without a type 2 diabetes diagnosis made up 17.5% of the low-dose liraglutide cohort and 2.7% of the cohort of other GLP-1 receptor agonists.

    In plain wordsIn a US database, 17.5% of low-dose liraglutide users had no diabetes diagnosis, against 2.7% of users of other GLP-1 drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicableShare of patients without a type 2 diabetes diagnosis
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Patterns of use · Metabolic and weight

    Measurements

    Patients without T2D diagnosis
    17.5%
    low-dose liraglutide cohort
    Patients without T2D diagnosis
    2.7%
    other GLP-1 RA cohort

    Source sentences

    Summary
    For the entire study period, Humedica data revealed that patients without T2D accounted for 2.7% of the GLP-1 RA cohort and 17.5% of the LD-L cohort.
    2 context sentences
    Summary · context
    This was a retrospective, repeated cross-sectional, cohort study.
    Summary · context
    Adult patients with T2D with more than 1 prescription for a GLP-1 RA in the Optum Humedica database between December 2014 and March 2016 were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneObservational studyOther

    In a US database, patients receiving low-dose liraglutide were more than 6 times as likely to have no indication of type 2 diabetes as patients taking other GLP-1 receptor agonists.

    In plain wordsIn a US database, low-dose liraglutide users were more than 6 times as likely to have no diabetes diagnosis as users of other GLP-1 drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicableLikelihood of no T2D indication, low-dose liraglutide versus other GLP-1 RAs
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Patterns of use · Metabolic and weight

    Measurements

    Likelihood of no T2D indication
    > 6 times
    low-dose liraglutide vs other GLP-1 RAs

    Source sentences

    Summary
    Multivariable logistic regression analyses identified that patients receiving LD-L were more than 6 times likely to have no indication of T2D relative to patients taking other GLP-1 RAs.
    2 context sentences
    Summary · context
    This was a retrospective, repeated cross-sectional, cohort study.
    Summary · context
    Adult patients with T2D with more than 1 prescription for a GLP-1 RA in the Optum Humedica database between December 2014 and March 2016 were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.